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C
hemotherapy relies heavily on small
therapeutic compounds, many of
which are difficult to formulate
and administer or suffer from biodistribu-
tion problems. Three main strategies have
evolved to address these issues: direct drug
modification to create a new drug with
altered physicochemical properties, drug
solubilization with excipients, and/or drug
encapsulation within delivery systems.1,2
Of special importance is the ability of
drug delivery systems to effectively deliver
therapeutic agents to targeted tissues,
thereby reducing the required dosage and
preventing the toxic effects of excipients
and drug interactions with off-target tissues.
Nanoparticle (NP) delivery systems focus pre-
dominantly on dendrimers, polymers, viruses,
and liposomal formulations.36 However,
these technologies often rely upon materials
that can vary greatly in size, composition, ease
of preparation, dispersion, and immunogeni-
city. To address these issues, we have been
studying the feasibility of bioengineering
vaults as a next-generation drug delivery sys-
temgiven their collectively uniqueadvantages
of being naturally occurring, monodispersed,
biocompatible, and nonimmunogenic.7
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ABSTRACT We report a novel approach to a new class of bio-
engineered, monodispersed, self-assembling vault nanoparticles
consisting of a protein shell exterior with a lipophilic core interior
designed for drug and probe delivery. Recombinant vaults were
engineered to contain a small amphipathic R-helix derived from the
nonstructural protein 5A of hepatitis C virus, thereby creating within
the vault lumen a lipophilic microenvironment into which lipophilic
compounds could be reversibly encapsulated. Multiple types of
electron microscopy showed that attachment of this peptide resulted in larger than expected additional mass internalized within the vault lumen
attributable to incorporation of host lipid membrane constituents spanning the vault waist (>35 nm). These bioengineered lipophilic vaults reversibly
associate with a sample set of therapeutic compounds, including all-trans retinoic acid, amphotericin B, and bryostatin 1, incorporating hundreds to
thousands of drug molecules per vault nanoparticle. Bryostatin 1 is of particular therapeutic interest because of its ability to potently induce expression of
latent HIV, thus representing a preclinical lead in efforts to eradicate HIV/AIDS. Vaults loaded with bryostatin 1 released free drug, resulting in activation of
HIV from provirus latency in vitro and induction of CD69 biomarker expression following intravenous injection into mice. The ability to preferentially and
reversibly encapsulate lipophilic compounds into these novel bioengineered vault nanoparticles greatly advances their potential use as drug delivery
systems.
KEYWORDS: vaults . nanoparticles . drug delivery systems . bryostatin 1 . HIV latency
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Vaults, the largest known ribonucleoprotein com-
plex in eukaryotic organisms, derive their name from
their multiple-arched morphology reminiscent of
vaulted ceilings in gothic cathedrals.810 Native vaults
appear as hollow, thin-walled sub-100 nm ellipsoidal
structures with well-defined monodispersity, uniform
NP size of 67 nm  40 nm  40 nm, and mass of
∼13 MDa.11,12 Native vaults consist of multiple copies
of three different proteins: the major vault protein
(MVP, 100 kDa), vault poly(ADP-ribose) polymerase
(VPARP, 193 kDa), and telomerase-associated protein
1 (TEP1, 290 kDa) along with several copies of one
or more small untranslated vault-associated RNA
(vRNAs).8,9 MVP constitutes ∼75% of the native vault
particle mass, and exogenous expression of MVP alone
in insect cells is both necessary and sufficient for the
formation of hollow vault-like particles that are mor-
phologically identical to native vaults, but lack VPARP,
TEP1, and vRNA.13 Native and recombinant vaults
consist of 78 copies of MVP (39 per half vault), which
begin by protruding internally into the vault lumen at
the NP waistline and then proceed to run lengthwise
toward either vault cap, where they become externally
solvent exposed.11,14,15 Novel recombinant MVP-only
vaults have been created that not only retain native
vault architecture but also incorporate a variety of
functionalities internally and/or externally.7 Addition-
ally, the use of anMVP interaction domain (INT, 17 kDa)
derived from the C-terminus of VPARP has allowed for
novel vault formation. This INT domain associates non-
covalently with an internally facing MVP binding site
and can be used to internally package other proteins of
interest into the vault lumen via recombinant covalent
attachment to INT.16,17
Initial bioengineering of the vault for sequestering
small lipophilic compounds made use of a smaller NP
known as a nanodisk (ND).1821 NDs (1020 nm dis-
coidal lipoprotein complexes) were incorporated into
the vault lumen, where they encapsulated all-trans
retinoic acid (ATRA) for treatment against hepatocel-
lular carcinoma cells.22 However, this approach is
hindered by lipopolysaccharide-associated cytotoxi-
city and cumbersome synthesis.23 As such, we set out
to refine and simplify our approach for vault-mediated
drug delivery. Our search for a suitable candidate
yielded an interesting peptide derived from hepatitis
C virus (HCV). The nonstructural protein 5A (NS5A) is a
56 kDa viral phosphoprotein involved in HCV repli-
cation.2427 NS5A associates with the cytoplasmic
leaflet of host-cell endoplasmic reticulum membranes
along with other HCV proteins involved in viral replica-
tion. NS5A interaction with host membranes has been
mapped to the first 31 amino acids of the protein.28,29
NMR analysis of this region characterized it as an am-
phipathic R-helix (residues 525) of <4 nm in length
that functions as a monotopic (in-plane) membrane
anchor domain via lipophilic interactions between
strictly conserved R-helix tryptophan residues and
the acyl chains of the neighboring host phospholipids
(Figure 1A). Furthermore, the polar face of this amphi-
pathic R-helix also contains strictly conserved charged
residues arranged in an asymmetrical distribution
believed to have a putative functional role via interac-
tions with other components of the viral replication
complex.30,31 Interestingly, these properties also allow
for their self-association in water when membrane
surfaces are absent. As such, NS5A1-31 was selected
for recombinant attachment to the N-terminus of MVP
with the assessment that the peptide would self-
associate to form an internalized protein-based lipophilic
ring stabilized by complementation of ionic and van
der Waals forces of adjacent copies of the amphipathic
R-helix within the vault lumen (Figure 1B). Herein we
detail the covalent attachment of the NS5A1-31 am-
phipathic R-helix to MVP, which results in the forma-
tion of a new class of nanoparticles consisting of a self-
assembling protein shell with an internalized lipophilic
core that is capable of reversibly sequestering small
lipophilic compounds of interest for vault-mediated
drug delivery (Figure 1C).
RESULTS AND DISCUSSION
Amphipathic r-Helix Vault as a Self-Assembling Protein
ShellLipophilic Core Complex. Development of the vault
as a potentially viable drug delivery system is moti-
vated by the particles' inherent advantages: small
size, self-assembly, uniform composition, monodisper-
sity, nonimmunogenicity, and relative ease of bioengi-
neering. However, while encapsulation of recombinant
proteins within vaults has allowed for exploitation of
novel functionalities, the ability to successfully incor-
porate and retain small molecules of therapeutic value
has been relatively unexplored. Covalent attachment
of a small amphipathicR-helix from the hepatitis C viral
protein NS5A was proposed to yield vaults containing
a localized ring of lipophilic density lining the inter-
nal circumference of the NP as adjacent monomeric
copies of NS5A1-31 self-interact due to their intrinsic
properties.
Covalent attachment of NS5A1-31 to the N-terminus
of MVP did not inhibit MVP expression nor interfere
with vault self-assembly. During purification, the ma-
jority of these amphipathic R-helix-containing (AH)
vaults were collected within the 4045% layer of
a discontinuous sucrose gradient as well-defined,
intact monodispersed NPs, consistent with previous
vault studies. When examined by uranyl acetate nega-
tively stained transmission electron microscopy (TEM),
AH vaults are morphologically distinct from both
native and recombinant MVP-only vaults due to the
presence of a significantly large region within the vault
lumen that uncharacteristically lacks normal uranyl
acetate staining (Figure 2A). While the absence of dark,
uranyl acetate stained areas under TEM is reflective of
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structural features of the vault (i.e., the protein shell
itself), the high intensity of this nonstaining region
within most of the AH vaults is inconsistent with the
amount of additional mass conferred onto the NP via
covalent attachment of the 31 amino acid peptide
NS5A1-31 to the N-terminus of MVP despite all 78
copies of the peptide being localized internally into
the vault lumen at the NP waist.15 As such, we sus-
pected that this additional internalizedmass within AH
vaults might represent additional cellular components
that coassociated within the AH vault lumen via inter-
actions with the NS5A1-31 amphipathic R-helices. As
the intensity of this non-uranyl acetate staining region
within AH vaults appeared to vary from vault to vault,
we further hypothesized that it is dynamic in nature
and could therefore be altered. When purified AH
vaults were treated with 5% Tween 20 detergent fol-
lowed by repurification, this nonstaining region of
additional mass within AH vaults experienced a signi-
ficant loss in intensity, suggesting that a sizable portion
of the novel mass sequestered within the AH vault
lumen is detergent soluble and therefore not part of
the AH vault itself (Figure 2B).
Since TEM imaging of vaults does not faithfully
represent their true 3D structure, we turned to cryo-
electron tomography (cryoET) to further characterize
Figure 2. (A) Negative stain TEM of AH vaults showing significant internalized mass within a majority of the NPs (white
arrowheads). (B) Negative stain TEM of AH vaults following treatment with 5% Tween 20 indicating a loss in the internalized
mass prominence and frequency, suggesting a dynamic, detergent-soluble nature. (C) CryoET tilt image showing the
internalized additional mass associated with AH vaults can traverse the entire vault lumen (complete, white arrowheads;
incomplete, white arrows).
Figure 1. (A) NMR-resolved three-dimensional structure of the hepatitis C NS5A1-31 amphipathic R-helix domain high-
lighting its asymmetric charge distribution along the polar face (PDB 1R7E). Hydrophobic residues are in black, while polar
residues are in yellow with acidic (Glu/Asp) and basic (Arg/Lys) functional groups in red and blue, respectively. The cysteine
residue SH is in green. (B) Simplified cartoon cutaway schematic of an AH vault depicting the attachment of NS5A1-31
amphipathic R-helix to MVP with subsequent vault self-assembly and self-association of adjacent NS5A1-31 amphipathic
R-helices to form an internalized lipophilic ring for sequestering small therapeutic compounds. (C) Three sample therapeutic
compounds that become reversibly associated within AH vaults.
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this additional mass within AH vaults in their frozen
hydrated state in three dimensions. CryoET tilt cross-
section slices revealed that a majority of AH vaults
contained internalized mass that completely traverses
the vault lumen (white arrowheads), a significant
distance of >35 nm with an apparent thickness of
∼35 nm (Figure 2C). Additionally, a minority of AH
vaults showed incomplete luminal coverage (white
arrows). CryoET tomography tilt slices and segmentation
of the 3D reconstructions of various well-defined AH
vaults further confirmed that this novel additional mass
sequestered within the lumen retains a dynamic mor-
phology (Figure 3AE). Additionally, AH vaults lacking
such internalized mass (before or after detergent
treatment) remain morphologically identical to a wide
variety of recombinant vaults containing short peptide
sequences of various length/composition/functionality
at the N-terminus of theMVP, implying that the unique
identity of NS5A1-31 itself must be responsible
for mediating the encapsulation of this unknown
additional internalized mass within these AH vaults
(Figure 3FH).
The ability of this novel internalized mass to span
the entire vault waist must be therefore attributable to
the presence of additional cellular components, which
we hypothesized to be host membrane lipid constitu-
ents (phospholipids, glycolipids, sterols, fatty acids,
etc.) given NS5A1-31's natural in vivo function as a
monotopic lipid membrane anchor. The lack of con-
taminating proteins, DNA, or RNA within purified AH
vaults, as well as dynamic morphological nature, also
helps support the interpretation that this internally
associated mass is constituted by various lipophilic
material interacting with the 78 copies of NS5A1-31
Figure 3. CryoET tilt slices of three AH vaults with varying levels of internalized density: (A) z-plane cross section and (B)
xy-plane cross section. CryoET segmented 3D reconstructions of the three different AH vaults: (C) exterior view, (D) xy-plane
cross section, and (E) z-plane cross section. (F) CryoET tilt-slice cross section along the z-plane of a single AH vault identified as
lacking internalizedmass. (G) CryoET segmented 3D reconstruction of the same emptyAH vaultwith z-plane cross sectioning.
(H) Prior cryoET 3D reconstructions sectioned along the z-planeofMVP-only vaults (left) andHis-T7-taggedMVPvaults (right).
His-T7 is a 31 amino acid unstructured peptide that does not span the entire vault lumen and is shown here to illustrate the
contrasting ability of the NS5A1-31 peptide (adapted from Mikyas et al.).15
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that line the inner circumference of the vault waistline.
To test this hypothesis, AH vaults were subsequently
incubated with the lipophilic dye 1,10-dioctadecyl-
3,3,30,30-tetramethylindodicarbocyanine perchlorate
(DiD), a long-chain dialkylcarbocyanine analogue that
increases fluorescent intensity in the presence of a
lipophilic environment.32 DiD showed a distinct quali-
tative increase in fluorescence upon co-incubation
with AH vaults compared to free dye or dye incubated
with control vaults, thereby corroborating an improved
lipophilic nature associated with AH vaults. Such an
internalized lipophilic core of 35 nm in thickness and
>35 nm in diameter would represent ∼4800 nm3 of
lipophilic volume within the NP available for absorp-
tion of lipophilic compounds of interest.
Drug-Binding Properties of AH Vaults. To test the ability
of purified AH vaults to bind therapeutic compounds,
we examined their ability to selectively retain either
doxorubicin (DOX), amphotericin B (AMB), or ATRA,
three small therapeutic molecules of varying lipophili-
city and aqueous solubilities. The AH vaults and
drugs were co-incubated, and the resulting complexes
separated over an overnight discontinuous sucrose
gradient. While AH vaults sediment into the denser
layers of the gradient due to their large molecular
mass, non-vault-associated materials remain in the
lighter layers of the gradient and are subsequently lost
during the final ultracentrifugation at 100000g as the
NPs are pelleted. In the case of DOX, a fluorescent
cytotoxic anthracycline antibiotic, neither control nor
AH vaults showed any detectable retention of com-
pound in the collected vault fraction, which is in
general agreement with DOX's high water solubility
of >50 mg/mL despite a lipophilicity partition constant
(LogP) of 1.27.33
Conversely, AMB, an antifungal amphipathic poly-
ene antibiotic with poor water solubility at physiologi-
cal pH of less than 0.75 mg/mL despite a LogP of 0.8,
was selectively retained by AH vaults during separation
with 45 molecules of AMB per single AH vault, while
control vaults showed no detectable AMB association
(Figure 4A).34 Similarly, ATRA, a highly toxic vitamin
A-derived retinoid that regulates gene transcription
with near absolute water insolubility and corre-
lated LogP of 6.30, coassociated with AH vaults at
182 molecules of the drug per single AH vault
(Figure 4B).22 However, ATRA appears to have some
nonspecific association with the NP itself, as seen by its
low level of association with the control vaults. The
higher loading efficacy of ATRA (∼75%) over AMB
(∼50%)might be reflective of the innate physicochem-
ical properties between these compounds and consis-
tent with the greater lipophilicity of ATRA. Since the
potential volume of such a lipophilic microenviron-
ment internalized within AH vaults could be as large as
∼4800 nm3, it is plausible for thousands to tens of
thousands of hydrophobic molecules to be encapsu-
lated within a single AH vault. As such, our initial
experimental values represent only a small fraction of
their theoretical maximum capacity.
To better address maximal loading of AH vaults, we
conducted smaller scale drug-loading experiments
with higher titrated ratios of drug to vault. Instead of
the previous 1 μg to 100 μg ratio used above, we
incubated 100 μg of control or AH vaults with 10 or
50 μg of AMB (Table 1). Following incubation, vaults
and their associated drug cargo were recovered from
excess, unboundmaterial by passage through amicro-
scale gel filtration spin column. Control vaults showed
low levels of drug retention of 264 and 431 molecules
of AMB per single control vault for the two respective
loading conditions. In contrast, AH vaults showed
considerably higher AMB retention following post
column separation with 1213 and 2071 molecules of
AMB per single AH vault for the two conditions. It
seems likely that the AMB seen in the recovered control
Figure 4. Spectrophotometric analysis showing the adsorption spectra for AMB (A) and ATRA (B) after incubation with either
control (solid line) or AH vaults (dotted line) with subsequent repurification of vaults via ultracentrifugation over a
discontinuous sucrose gradient. Spectra represent the 4045% layer where vaults sediment.
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vault samples represent a weak and/or transient non-
specific drugvault interaction that occurs at these
higher AMB to vault ratios. Meanwhile, the 45-fold
increase in AMB associated with the AH vaults is
apparently due to sequestration of the drug in their
large lipophilic microenvironment. The calculated
values from the 10 and 50 μg AMB:100 μg AH vault
samples do not violate the starting ratio of 815:1.
Rather the observed 1213 and 2071 AMB per single
AH vault stems from inefficient vault recovery over the
gel filtration spin column, which leads to an apparent
overcalcultion of the loading efficiency.
Following a 1-week storage at 4 C, the drug-bound
vaults were re-examined. Control vault samples experi-
enced a mild to severe drop in AMB content (18% loss
for the 10 μg sample and 47% for the 50 μg sample,
respectively). Conversely, AH vaults experienced only a
minor drop in associated drug with 90% or greater of
the original AMB being retained (11% loss for the 10 μg
sample and 6% for the 50 μg sample, respectively). This
loss of AMB in the control vault samples may be
indicative of poor protection from the aqueous envi-
ronment, thereby allowing faster molecular decompo-
sition in line with AMB's general stability. Meanwhile,
the negligible loss of AMB in theAHvault samples likely
results from the drug molecules being sequestered
within the NP's lipophilic core, which provides greater
overall stability and protection. The ability of AH vaults
to encapsulate >2000 drugmolecules while potentially
offering a more hospitable microenvironment is an
important milestone in their development as a novel
excipient reservoir for solubilizing lipophilic therapeu-
tic compounds for drug delivery.
AH Vaults for Treating HIV Latency Using Bryostatin 1. As an
initial clinical application for the AH vaults, we focused
on the delivery of bryostatin 1, a promising therapeutic
lead for the treatment of Alzheimer's disease, cancer,
and HIV/AIDS eradication. Bryostatins are a family of
macrolide lactone compounds with potent neurobio-
chemical, anticancer, and immuno-modulating prop-
erties both in vitro and in vivo, which operate putatively
through modulation of protein kinase C (PKC).35,36
While practical access to the bryostatins from natural
sources (e.g., Bugula neritina), engineered biosynthesis,
and total synthesis are still works in progress, more
accessible, designed, and highly potent analogues are
now becoming available.37 However, little attention
has been directed at the formulation and delivery of
these agents, issues that are of huge significance to
preclinical studies on both the natural and designed
analogues.
Our specific interest in bryostatin and their ana-
logues (bryologues) is driven in part from their poten-
tial use in the eradication of HIV/AIDS. In the span of a
generation, AIDS/HIV has undergone a remarkable
transformation from a lethal infection to a largely man-
ageable chronic disease. However, over 33 million
people remain infected with the virus. Highly active
antiretroviral therapy (HAART) currently reduces viral
activity to undetectable levels, thereby slowing disease
progression. However, HAART does not address the
issue of provirus latency within cellular reservoirs,
which can resupply active virus. Latently infected
CD4þ T cells can persist for decades in HAART-treated
individuals and therefore represent a key barrier to
disease eradication.38 One potential method for elim-
inating the latent reservoir of HIV is to induce the
dormant provirus to express viral proteins, which
would make the host cell susceptible to immune
effector mechanisms, viral cytopathic effects, and ad-
ditional therapies directed toward viral proteins such as
anti-HIV envelope immunotoxins.39 Delivery of latency
activators using nanoparticles could afford a variety of
benefits, including the combinatorial and targeted in-
troduction of these agents specifically to the cell type of
choice, leading to less toxicity associatedwith activation
of nontarget cell types. To explore this possibility, we
previously introduced bryostatin 1 into lipid nanoparti-
cles and demonstrated that these particles activate
latent HIV and can also be targeted toward CD4þ T
cells using monoclonal antibodies.40 Here we have
incorporated bryostatin 1 into AH vault particles and
evaluated their properties in vitro and in vivo.
Bryostatin 1 (LogP of 4.255.40, predicted) in-
corporation into AH vaults was assessed by high-
performance liquid chromatography (HPLC) coupled
withmultiple reactionmonitoring (MRM) tandemmass
spectrometry (MS/MS) in lieu of spectrophotometric
analysis.41 MRM-LC-MS/MS allowed for sensitive detec-
tion (>0.009 ng/μL) of the sodiated bryostatin 1 ion at
m/z 927.4, consistentwith previous reports.42 AH vaults
were co-incubated for 30 min at 4 C with bryostatin 1
and subsequently collected from solution using ultra-
centrifugation at 100000g. Aliquots of the starting
material, spin supernatant, and the resuspended vaults
were analyzed by MRM-LC-MS/MS, and the bryo-
statin 1 concentration was measured using a standard
curve generated using known concentrations of
TABLE 1. AH Vault Drug-Loading Capacity Using Amphotericin B vs Control Vaults
AMB:vault starting ratio (M) AMB:vault ending ratio (M) AMB:vault ending ratio (post 7 days) (M) % change
control vault 10 μg:100 μg (815:1) 32.6 ng:1 μg (264:1) 26.8 ng:1 μg (217:1) 18% V
50 μg:100 μg (4075:1) 53.0 ng:1 μg (431:1) 28.0 ng:1 μg (228:1) 47% V
AH vault 10 μg:100 μg (815:1) 149.2 ng:1 μg (1213:1) 133.6 ng:1 μg (1085:1) 11% V
50 μg:100 μg (4075:1) 254.7 ng:1 μg (2071:1) 240.8 ng:1 μg (1958:1) 6% V
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bryostatin 1. Approximately 10.6( 1.4 ng of bryostatin
1 was measured in the incubated, precentrifuged
sample and is in accordancewith the expected value of
10 ng/μL (1 μg of bryostatin 1 per 100 μg of AH vault in
100 μL of PBS). Meanwhile, the 13.4 ( 2.3 ng of
bryostatin 1 measured in the resuspended vault pellet
is within experimental error and indicates that approxi-
mately 100% of the starting bryostatin 1 was retained
through association with the AH vaults with ∼83 mol-
ecules of the drug per single AH vault. However,
because of the low availability and high cost associated
with bryostatin 1, only a few initial studies were con-
ducted using control vaults.
Compared to emptyAH vaults, AH vaults containing
bryostatin 1 showed clear dose-dependent activation
of latent HIV provirus in the J-Lat 10.6 cell line, a
well-characterized model for the main T-lymphocyte
cell reservoir, with activity starting at 1 ng/μL of AH
vaults (Figure 5A). Alternatively, stimulation of T cells
with PKC-activating compounds, such as bryostatin 1,
induces cell surface expression of CD69, which occurs
at similar concentrations to those required to activate
HIV from latency.43,44 As such, CD69 expression can be
used as a biomarker for evaluating whether bryostatin
1 delivered via association with AH vaults remains
bioactive in the desired T cell type. When tested for
activity in this way, bryostatin 1-loaded AH vaults
activated CD69 expression in primary human periph-
eral blood mononuclear cells (PBMCs) obtained from
four different donors in a dose-dependent manner
with stimulation occurring at concentrations as low
as 0.1 ng/μL AH vaults as analyzed by flow cytometry
Figure 5. (A) In vitro latent HIV activation usingbryostatin 1-loadedAHvaults on J-Lat 10.6 cells for 48 h. In these assays 50 nM
bryostatin 1 compound (without vaults) was used as a positive control and induced GFP expression in 30.6% ((0.6%) of cells.
Error bars indicate(1 SD (N = 3). NS not significant, **p < 0.0001 empty vault vs vaultþ bryostatin 1 (2-sided t test). (B) In vitro
stimulationofCD69 (HIVprovirus latencyactivationbiomarker) activationusingbryostatin 1-loadedAHvaults onprimaryhuman
PBMCs for 24 h. Positive control stimulations with 50 nM bryostatin 1 compound (without vaults) induced CD69 expression in
69.4% ((31.3%) of cells. Error bars indicate(1 SD (N=4different cell donors). NS not significant, *p<0.01 empty vault vs vaultþ
bryostatin 1 (2-sided t test). (C) In vivoCD69 stimulation fromharvestedC57/bl6mouse splenocytes at 24hpostinjection of either
media control, bryostatin 1, bryostatin 1-loaded AH vaults, or empty AH vaults. Error bars indicate(1 SD (35 mice per group).
TABLE 2. Summarization of Bioengineered AH Vaults’ Ability to Selectively Associate with a Small Sample Set of
Therapeutic Compounds with Different Physicochemical Properties via Noncovalent, Reversible Association within a
Novel Internalized Lipophilic Core Microenvironment Generated by the Covalent Attachment of a Unique Amphipathic
R-Helix Peptide (NS5A1-31) to the MVP
therapeutic
compound
solubilityH2O
(mg/mL)
LogP
(octanol/water) loading condition
drug:vault
starting ratio (M)
drug:vault
ending ratio (M) detection method
doxorubicin
(580 g/mol)
50 1.27 (PubChem) 0.5 h at 4 C,
20 h centrifugation
10 μg:1000 μg
(129:1)
none detected UV/vis spectra, DOXε480nn =
11 500 M1 cm1
amphotericin B
(924 g/mol)
0.75 0.8 (DrugBank) 0.5 h at 4 C,
20 h centrifugation
10 μg:1000 μg
(80:1)
5.6 ng:l μg
(45:1)
UV/vis spectra, AMBε406 nm =
150 000 M1 cm1
0.5 h at 4 C, 5 min
spin column
10 μg:100 μg
(815:1)
149.2 ng:l μg
(1213:1)
UV/vis spectra, AMBε406 nm =
150 000 M1 cm1
0.5 h at 4 C, 5 min
spin column
50 μg:100 μg
(4075:1)
254.7 ng:l μg
(2071:1)
UV/vis spectra, AMBε406 nm =
150 000 M1 cm1
all-trans retinoic
acid (300 g/mol)
insoluble 6.30 (DrugBank) 0.5 h at 4 C,
20 h centrifugation
10 μg:1000 μg
(250:1)
7.3 ng:l μg
(182:1)
UV/vis spectra, ATRAε350 nm =
44,300 M1 cm1
bryostatin 1
(905 g/mol)
insoluble 4.255.40
(predicted, ChEMBL and
ChemSpyder)
0.5 h at 4 C,
1 h centrifugation
1 μg:100 μg
(83:1)
13.4 ng:l μg
(83:1)
mass spec (MRM-LC-MS/MS)
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(Figure 5B). To evaluate whether these drug-loaded
vaults are also bioactive in vivo, they were injected into
C57/bl6 mice at 1 μg of bryostatin 1 per 100 μg of AH
vaults per mouse. At 24 h postinjection, over 90% of
CD4þ T cells present within harvested splenocytes had
been induced to express CD69, demonstrating that the
bryostatin 1-loaded AH vaults can successfully deliver
compounds in vivo (Figure 5C). Notably, these untar-
geted vaults also induced >70% of non-CD4þ T cells
(primarily CD8þ T cells) and ∼40% of non-T cells to
express CD69. This activation of a broad spectrum of
cell types illustrates the potential benefits of targeting
the vaults more selectively to the cell type of interest
(in this case, to CD4þ T cells). Methods for targeting
vaults are available and are currently being explored.45
Further improvements to the HIV provirus latency
activating AH vaults could also be achieved by
using more potent analogues of bryostatin or
prostratin.36,43,46 Second-generation AH vaults could
therefore include both targeting moieties and en-
hanced latency-activating compounds.
CONCLUSIONS
These experiments demonstrate the novel ability of
AH vaults to encapsulate various therapeutic com-
pounds, up to >2000 molecules per single AH vault,
through reversible association with a highly lipophilic
interior that results from the covalent attachment
of an amphipathic R-helical peptide to the MVP
(summarized in Table 2). Furthermore, these drug-
loaded AH vaults can deliver their therapeutic cargo,
such as bryostatin 1, in vitro using both cultured and
primary cell lines, as well as in vivo. The formation of
these self-assembling protein shelllipophilic core
NPs benefits not only from the key properties of vaults
such as monodispersity, cell specific targeting, and
biocompatibility, but also from being a vault-drug
formulation based approach that can completely
internalize their cargo, thereby offering an additional
layer of protection. As such, these novel AH vaults
represent an interesting “proof of concept” approach
to functionalizing the vault for potential use in drug
delivery.
MATERIALS AND METHODS
AH Vault Cloning, Expression, and Purification. NS5A1-31 was PCR
amplified from a construct containing HCV NS5A1-31 fused to
GFP generously provided by Darius Moradpour M.D. at the
Centre Hospitalier Universitaire Vaudois, University of Lausanne,
Switzerland. The following primers were used to generate a
∼100 bp PCR fragment with flanking Nco I restriction sites
(underlined). Forward: 5
0
GAATTCACCATGGCCGGTTCCTGGC30 ,
Reverse: 5
0
CCTTGCTCACCCATGGTTGGCATGAG30 . The resulting
PCR fragment contained the amino acid residue sequence
MAGSWLRDIWDWICEVLSDFKTWLKAKLMPTM, which incorpo-
rates a start Met, as well as two codon sequence changes
(Ser1Ala andGln31Thr, underlined) expected to behave as silent
mutations with no anticipated consequence on the structural
folding of the amphipathic helix domain contained from resi-
dues 525. Residue Leu31 is replaced with the start Met of MVP
(underlined, bold). Subsequent Nco I digestion was used to
insert NS5A1-31 immediately upstream, in-frame to rat MVP
cDNA previously cloned into pFastBac-1 vector using standard
molecular biology techniques. This construct was subsequently
used to establish a baculovirus used in Sf9 (Spodoptera
frugiperda) cell expression, as previously detailed elsewhere.13
Purification of AH vaults was conducted using standard vault
purification protocol with isolated vaults collected within the
40% or 45% layer of a semidiscontinuous sucrose gradient and
stored in 1 PBS at 4 C. Roughly 1020% of total AH vaults
assembled into larger structures called vaultimers, located
primarily in the 50% sucrose gradient fraction, which have been
previously observed.13 Detergent treatment of AH vaults was
carried out by incubating purified vaults in 1 PBS þ 5%
Tween 20 for 1 h at 4 C with rotation and repurified according
to standard methods.
AH Vault Transmission Electron Microscopy, Cryo-electron Tomography,
and Segmentation. Negative staining and TEM were conducted
using a JEM 1200EXmicroscope (JEOL) equippedwith a Bioscan
600 W digital camera (Gatan Inc.). Cryogenically frozen samples
were prepared on Quantifoil grids by plunge freezing. An FEI
Tecnai F20 transmission cryo-electron microscope was used
to acquire tomography tilt series from 70 to þ70 with the
batch tomography program (FEI). The tilt series were recorded
on a 16 megapixel TVIPS CCD camera with a total electron
dosage of about 100 electrons on each imaged sample area and
amagnification that gives a pixel size of 0.45 nm per pixel at the
specimen level. The tomography tilt series were processed with
a suite of programs to generate a segmented 3D reconstruction
as follows. First, the series were precisely aligned using the
eTomo program from the Imod package. Rough alignment was
performed by cross-correlation of images in the tilt series,
followed by fine alignment using 10 nm gold beads as fiducial
markers. A boundary model was created to adjust the tilt axis
before a final, precisely aligned tilt stack was produced for each
series. The aligned tilt series was then used to make a 3D
reconstruction using GPU-based SIRT (simultaneous iterative
reconstruction technique) reconstruction implemented in the
Inspect3D program from FEI. The 3D reconstructions were
saved as a stack of xy sections stacked along the z direction.
This 3D tomographic reconstruction was further processed by
median filtering and pixel binning to enhance structural con-
trast. Individual vault particles were then segmented from the
3D density maps and displayed by volume renderings of the
vault particles with packaged material with Amira (Visage Inc.).
For densities corresponding to the vault particle, the known
39-fold symmetry was imposed to improve the signal-to-noise
ratio for volume rendering.
AH Vault Drug Packaging and Spectrophotometric Analysis. AH vault
lipophilicity was initially assayed using 5 μL of a 10 μg/μL
1,10-dioctadecyl-3,3,30 ,30-tetramethylindodicarbocyanine per-
chlorate (DiD(644 ex/665 em), Invitrogen Molecular Probes), di-
methyl sulfoxide (DMSO) stock added to 1000 μg of prepurified
AH vault, control vault, bovine serum albumin (Sigma), or alone
in 1 PBSbuffer for 30min at 4 Cwith rotation and protection
from light. Samples were overlaid onto 1 mL of 1 PBS buffer
in TLA100.1 rotor tubes (Beckman Coulter) and ultracentrifuged
at 100000g for 1 h at 4 C. Pellets were resuspended in 100 μL of
1 PBS buffer, and fluorescence was measured at 665 nm.
Retention of either doxorubucin (Sigma), amphotericin B
(Sigma), or all-trans retinoic acid (Sigma) was conducted as
follows: 1000 μg of prepurified AH or CP vaults was incubated
with 10 μg of each respective compound from appropriate
stocks into 1 mL of 1 PBS buffer for 30 min at 4 C with rota-
tion and protection from light. Samples were overlaid onto
a semidiscontinuous sucrose gradient and centrifuged at
25 000 rpm (77000g) using a Beckman SW41 Ti swinging bucket
rotor for 16 h at 4 C on a Beckman-Coulter ultracentrifuge.
Gradient fractions were collected and ultracentrifuged for 2 h at
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40 000 rpm (100000g) to pellet vaults. Collected pellets were
resuspended in 1 PBS buffer and assayed for purity by either
SDS-PAGE with Coomassie blue staining or by Western blotting
and quantitated by bicinchoninic acid (BCA). Collected fraction
samples were standardized to [vault] = 1 μg/μL and further
diluted 1:10 for UV/vis absorbance spectroscopy in a 100 μL
microquartz cuvette from 300 to 450 or 300 to 600 nm with
the long wavelength of vault-only control samples adjusted
to baseline. Compound concentration was calculated using
known molar extinction coeffecients (DOX ε480 nm = 11 500
M1 cm1(water), AMBε406 nm = 150 000 M
1 cm1(methanol),
ATRAε350 nm = 44 300 M
1 cm1(ethanol)).
Alternatively, small-scale drug loading in control or AH
vaults was conducted in a semianalogous manner. Either 10
or 50 μg of AMB was added to 100 μg of prepurified control or
AH vaults in PBS buffer to a total volume of 100 μL for 30min at
4 C with rotation and protection from light. Samples were then
applied directly to Micro Bio-Spin P6 gel columns (Bio-Rad) that
were pre-equilibrated with four washes of 400 μL of 1 PBS
buffer and centrifuged for 4 min at 1000g at room temperature
to collect vaults and associated AMB within the filtrate. Control
AMB in 1 PBS buffer alone was completely (100%) removed
from the filtrate following passage over the gel filtration
column. Collected filtrates were analyzed for vault concentra-
tion using BCA, while AMB concentration was assayed using the
previously mentioned knownmolar extinction coefficient using
a Nanodrop 1000 (Thermo Scientific). Samples were stored at
4 C and reassayed after 1 week.
AH Vault Packaging of Bryostatin 1. A 1 μg amount of bryostatin-
1 (Tocris Bioscience) in ethanol was incubated with 100 μg of
prepurified AH vaults (1 wt %/wt) in 100 μL of 1 PBS for
30min at 4 C. A small aliquot of this startingmaterial was saved
for analysis, and the remaining suspension treated with ultra-
centrifugation at 53 000 rpm (100000g) for 1 h at 4 C in
TLA100.1 rotor tubes on a Beckman Coulter tabletop ultracen-
trifuge. Supernatant, containing any unbound bryostatin 1, was
carefully aspirated and saved for analysis. The AH vault pellet
was resuspended in 50 μL of 1 PBS and incubated overnight
at 4 C with gentle rotation. Aliquots of the starting material
(bryostatin 1 and prepurified AH vaults prior to centrifugation),
centrifugation supernatant, and resuspended centrifugation
pellet were prepared for HPLC-MRM-MS/MS analysis.
AH Vault Bound Bryostatin 1 Quantitation by Liquid Chromatography
Mass Spectrometry. Bryostatin 1 AH vault starting material, super-
natant, and resuspended pellet were analyzed to determine
binding of bryostatin 1 to AH vaults. A 1μL sample of each of the
three samples was diluted 1:200 in pure methanol and trans-
ferred to an autosampler vial containing a 0.2 mL glass insert.
Injections of 25 μL were made onto an Agilent 1200 HPLC
system using an Agilent Zorbax 300SB-C3 (3 μm, 2.1 cm 
150mm) column. Sampleswere eluted using a linear gradient of
100% solvent A (98%water, 2% acetonitrile, 0.1% formic acid) to
100% solvent B (98% acetonitrile, 0.1% formic acid) over 10 min
with a 4 min isocratic hold at 100% solvent B at a flow rate of
250μL/min. Then 25μL injections of 0.1% formic acidwere inserted
throughout the run to assess and address bryostatin 1 carryover
in sequential analyses. The sodiated bryostatin 1 [M þ Na]þ ion
was monitored on an AB Sciex 4000 QTRAP triple quadrupole
mass spectrometer outfitted with a Turbo Spray ESI source.
The instrument was operated with 5500 V applied to the ESI
source and a capillary temperature of 250 C. Bryostatin 1 was
analyzed in MRM mode, measuring three separate precur-
sorproduct ion transitions:m/z 927.4f 867.4, 927.4f 593.3,
and 927.4 f 549.3. The average peak area of all three
bryostatin 1 transitions was determined for each analysis using
Analyst 1.4.2 software for transition peak integration. Each
sample was run in triplicate except for the supernatant, which
was analyzed only once. A stock solution of bryostatin 1 in pure
methanol was prepared at a concentration of 905 ng/μL. This
stock solution was then serially diluted in methanol to con-
struct a standard curve at the following concentrations: 0.009,
0.045, 0.090, 0.225, and 0.450 ng/μL. Standard bryostatin
1 samples were analyzed using the same instrument and
method parameters listed above. All measurements were
performed in triplicate.
AH Vault Packaged Bryostatin 1 in Vitro HIV Latency Stimulation and
Analysis. J-Lat clone 10.6 cells were obtained from the AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH. These cells were cultured in RPMI medium 1640
(Invitrogen) containing 10% fetal bovine serum (Omega
Scientific) and 100 units/mL of penicillin and 100 μg/mL of
streptomycin (Invitrogen). During stimulation cells were seeded
at a concentration of 50 000 cells/well in a V-bottomed 96-well
plate containing the relevant concentration of vaults in 100 μL
of RPMImedia. Cells were incubated for 48 h and then harvested
by washing with fresh media and resuspending pellets in
2% paraformaldehyde. The percentage of GFPþ cells was
quantified by flow cytometry using a LSRFortessa machine
(BD Biosciences).
AH Vault Packaged Bryostatin 1 Human PBMC in Vitro CD69 Stimulation
and Analysis. Peripheral blood mononuclear cells isolated using
Ficoll-Paque Plus separation (GE Healthcare) from HIV sero-
negative donors were obtained from the UCLA Virology Core.
Cells were placed in V-bottomed 96-well plates at a density of
100 000 cells per well in a 200 μL volume of RF10 media
containing the indicated vaults. Media only and stimulation
with 50 nMbryostatin 1 compound alonewere used as controls.
Cells were incubated for 48 h before harvesting for analysis
using flow cytometry.
AH Vault Packaged Bryostatin 1 in Vivo Animal CD69 Stimulation and
Analysis. Animal experiments were approved by the UCLA ani-
mal research committee and conformed to all local and national
guidelines and regulations. C57/bl6 mice were obtained from
the UCLA Department of Radiation Oncology. A 100 μg amount
of AH vaults at 10 ng of bryostatin 1 per 1 μg of vault was
resuspended in 150 μL of RPMI media and then administered
intravenously via retro-orbital injection. At 24 h postinjection
mice were sacrificed and the spleens isolated. Spleens were
disaggregated by forcing tissue through a steel mesh and then
filtered through a 40 μm filter to produce a single-cell suspen-
sion. These cells were then stained for flow cytometry to analyze
surface expression of relevant markers.
Flow Cytometry Analysis of Cell Surface Markers. Cells were stained
by first suspending them in 50 μL of a 1:1 mix of 1 PBS and
human AB serum (Sigma). For human PBMC analysis the cells
were stained with anti-human CD69-phycoerythrin (Beckman
Coulter). For mouse splenocyte analysis the cells were stained
with a combination of anti-mouse CD3-fluorescein isothio-
cyanate (eBioscience), CD69-phycoerythrin (eBioscience), and
CD4-peridinin chlorophyll protein (eBioscience). Following anti-
body addition, themixturewas incubated at 4 C for 15min. The
cells were thenwashed, resuspended in 1 PBS containing 2%
paraformaldehyde, and stored at 4 C. Fixed cells were analyzed
using an LSRFortessa (BD Biosciences). The resultant list mode
files were processed using FlowJo software (version 7.6).
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